Raymond James Financial Inc. Purchases Shares of 161,708 LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Raymond James Financial Inc. acquired a new position in LeMaitre Vascular, Inc. (NASDAQ:LMAT) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 161,708 shares of the medical instruments supplier’s stock, valued at approximately $14,900,000.

A number of other institutional investors also recently made changes to their positions in the business. Smartleaf Asset Management LLC lifted its stake in LeMaitre Vascular by 234.4% in the fourth quarter. Smartleaf Asset Management LLC now owns 418 shares of the medical instruments supplier’s stock worth $39,000 after purchasing an additional 293 shares during the last quarter. CBIZ Investment Advisory Services LLC increased its holdings in shares of LeMaitre Vascular by 38.5% in the fourth quarter. CBIZ Investment Advisory Services LLC now owns 421 shares of the medical instruments supplier’s stock worth $39,000 after buying an additional 117 shares during the period. KBC Group NV boosted its holdings in LeMaitre Vascular by 58.4% during the 4th quarter. KBC Group NV now owns 1,112 shares of the medical instruments supplier’s stock valued at $102,000 after acquiring an additional 410 shares during the period. Huntington National Bank boosted its holdings in LeMaitre Vascular by 64.9% during the 4th quarter. Huntington National Bank now owns 1,156 shares of the medical instruments supplier’s stock valued at $107,000 after acquiring an additional 455 shares during the period. Finally, Empowered Funds LLC purchased a new position in LeMaitre Vascular in the 4th quarter worth approximately $150,000. Hedge funds and other institutional investors own 84.64% of the company’s stock.

Insider Activity

In other LeMaitre Vascular news, insider Trent G. Kamke sold 2,009 shares of the business’s stock in a transaction on Wednesday, March 12th. The stock was sold at an average price of $82.12, for a total value of $164,979.08. Following the sale, the insider now directly owns 5,564 shares of the company’s stock, valued at approximately $456,915.68. The trade was a 26.53 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 10.79% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have recently weighed in on LMAT. Wells Fargo & Company assumed coverage on LeMaitre Vascular in a research note on Thursday, February 13th. They set an “equal weight” rating and a $95.00 price objective for the company. Barrington Research cut shares of LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a research report on Friday, February 28th. Lake Street Capital upped their price objective on shares of LeMaitre Vascular from $105.00 to $110.00 and gave the company a “buy” rating in a research note on Friday, February 28th. Finally, Oppenheimer downgraded LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a report on Friday, February 28th. Five equities research analysts have rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, LeMaitre Vascular currently has a consensus rating of “Moderate Buy” and an average price target of $95.25.

LeMaitre Vascular Stock Performance

Shares of NASDAQ:LMAT opened at $84.72 on Tuesday. The firm has a market capitalization of $1.91 billion, a P/E ratio of 46.30, a P/E/G ratio of 2.22 and a beta of 0.89. The stock has a 50 day moving average price of $87.62 and a 200-day moving average price of $93.47. LeMaitre Vascular, Inc. has a 52-week low of $62.40 and a 52-week high of $109.58.

LeMaitre Vascular (NASDAQ:LMAT) last announced its quarterly earnings data on Thursday, February 27th. The medical instruments supplier reported $0.49 EPS for the quarter, meeting the consensus estimate of $0.49. The business had revenue of $55.81 million during the quarter, compared to analyst estimates of $55.99 million. LeMaitre Vascular had a return on equity of 13.15% and a net margin of 19.40%. On average, equities analysts forecast that LeMaitre Vascular, Inc. will post 1.94 EPS for the current fiscal year.

LeMaitre Vascular Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, March 27th. Shareholders of record on Thursday, March 13th were paid a dividend of $0.20 per share. This is an increase from LeMaitre Vascular’s previous quarterly dividend of $0.16. The ex-dividend date of this dividend was Thursday, March 13th. This represents a $0.80 dividend on an annualized basis and a dividend yield of 0.94%. LeMaitre Vascular’s dividend payout ratio (DPR) is currently 41.24%.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.